查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405793

高雪氏症治疗药物市场规模、份额、趋势分析报告：按类型、治疗、按地区、细分市场预测，2023-2030 年

Gaucher Disease Drugs Market Size, Share & Trends Analysis Report By Type (Type 1, Type 2, Type 3, Others) By Therapy (Enzyme Replacement Therapy, Substrate Replacement Therapy, Others), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 84 Pages | 商品交期: 2-10个工作天内

价格

高雪氏症治疗药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2023年至2030年全球高雪氏症治疗市场规模将以2.6%的复合年增长率成长，2030年达到20.3亿美元。

该疾病盛行率的上升以及该领域研究和开发活动的活性化可能有助于推动未来几年的市场发展。鑑于大量未满足的需求，迫切需要开发新的治疗方法提高疗效、简化给药并降低神经毒性併发症的成本。

高雪氏症是一种由 GBA 基因突变引起的遗传性代谢疾病。高雪氏症的人产生的Glucocerebrosidase(GCase) 较少，而葡萄糖脑苷脂酶是分解Glucocerebroside所需的酵素。过多的脂质积聚在脾、肝、肾、脑、肺和骨髓中，干扰器官的正常功能。

儘管高雪氏症是最常见的溶小体贮积症，但它是一种罕见疾病，平均盛行率为十万分之一。然而，某些种族群体，例如德系犹太人，更容易感染这种疾病。德系犹太人的平均盛行率为五百分之一。

目前，最常见的高雪氏症类型是第 1 型。此疾病本质上是非神经病变的，因为它不影响中枢神经系统(CNS)。 2017年1型GD占市占率超过75.0%。预计这一地位将维持到2025年。类型 2 和类型 3 不如类型 1 常见。

从治疗方法来看，酵素替代疗法（ERT）是2017年市场收益的主要贡献者。该领域的成长是由 Cerezyme 和 Vpriv 的强劲销售推动的。然而，在 Cerdelga 和 Zavesca 的带领下，基材替代疗法 (SRT) 的趋势日益明显。 ERT 主要适用于 1 型和 3 型（解决与中枢神经系统无关的问题），因为补充酶无法穿过血脑障壁。此外，2型没有有效的治疗方法。

高雪氏症治疗药物市场报告亮点

  • 2型是三种GD中最罕见的一种，平均死亡率不到2年。
  • 以赛诺菲健赞 (Sanofi Genzyme) 的 Cerezyme 为代表的酵素替代疗法是治疗的支柱。然而，GD 治疗正在转向基材替代疗法。
  • 美国在销售和疾病负担方面均领先主要市场。由于患者基础不断扩大且获得治疗的便利性，预计该国将在 2030 年之前继续主导市场。
  • 进入该市场的知名公司包括赛诺菲健赞 (Sanofi Genzyme)、夏尔 (Shire)、辉瑞 (Pfizer) 和强生 (Johnson & Johnson)。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章高雪氏症治疗药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 高雪氏症治疗药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章高雪氏症治疗药物：类型估计与趋势分析

  • 高雪氏症症药物市场：要点
  • 高雪氏症治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 类型1
  • 2型
  • 类型3
  • 其他的

第五章高雪氏症治疗药物：治疗估计与趋势分析

  • 高雪氏症症药物市场：要点
  • 高雪氏症治疗药物市场：2022 年和 2030 年趋势和市场占有率分析
  • 酵素替代疗法
  • 基材交换疗法
  • 其他的

第六章高雪氏症治疗药物市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的高雪氏症治疗药物市场：主要市场点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第七章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Sanofi
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc
    • Johnson & Johnson Services, Inc.
    • ERAD Therapeutic
Product Code: GVR-2-68038-599-1

Gaucher Disease Drugs Market Growth & Trends:

The global gaucher disease drugs market size is expected to reach USD 2.03 billion by 2030, expanding at a CAGR of 2.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for the development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.

Gaucher disease is a genetic metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme required to degrade glucocerebroside. Excess accumulation of lipids in spleen, liver, kidney, brain, lungs, and bone marrow impedes the normal functioning of the organs.

In spite of being the most prevalent lysosomal storage disorder, Gaucher disease is a rare condition with an average prevalence of 1 in 100,000 individuals. However, certain ethnic races such as Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an average disease prevalence of 1 in 500 individuals.

Currently, type 1 is the most common form of Gaucher disease. This condition is nonneuronopathic in nature, as it does not affect the central nervous system (CNS). Type 1 GD commanded more than 75.0% of the market in 2017. It is estimated to retain its position through 2025. Type 2 and type 3 are not as common as type 1.

On the basis of treatment, enzyme replacement therapy (ERT) was the leading revenue contributor in the market in 2017. The growth of the segment can be attributed to the strong sales of Cerezyme and Vpriv. However, there has been an increase in inclination towards substrate replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly indicated for type 1 and type 3 (to address issues unrelated to the CNS), as replacement enzymes cannot penetrate blood brain barrier. Additionally, there is no effective treatment for type 2.

Gaucher Disease Drugs Market Report Highlights:

  • Type 2 is the rarest of the three forms of GD, with an average mortality rate of less than two years
  • Enzyme replacement therapy dominated the treatment landscape, headed by Sanofi Genzyme's Cerezyme. However, GD treatment is witnessing a shift towards substrate replacement therapy
  • The U.S. spearheaded the major markets, in terms of sales as well as disease burden. The country will continue to dominate the market through 2030, on account of widening the patient base and easy accessibility to treatments
  • Some of the prominent companies operating in the market are Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Therapy
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Therapy outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Gaucher Disease Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Gaucher Disease Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Gaucher Disease Drugs: Type Estimates & Trend Analysis

  • 4.1. Gaucher Disease Drugs Market: Key Takeaways
  • 4.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Type 1
    • 4.3.1. Type 1 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Type 2
    • 4.4.1. Type 2 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Type 3
    • 4.5.1. Type 3 market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Gaucher Disease Drugs: Therapy Estimates & Trend Analysis

  • 5.1. Gaucher Disease Drugs Market: Key Takeaways
  • 5.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Enzyme Replacement Therapy
    • 5.3.1. Enzyme replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Substrate Replacement Therapy
    • 5.4.1. Substrate replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Gaucher Disease Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Gaucher Disease Drugs Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Sanofi
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Takeda Pharmaceutical Company Limited
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Pfizer Inc
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Johnson & Johnson Services, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. ERAD Therapeutic
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 3 North America Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 4 North America Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 Canada Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 8 Canada Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 9 Europe Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 10 Europe Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 Europe Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 UK Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 13 UK Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 Germany Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 15 Germany Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 16 France Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 17 France Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 18 Italy Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 19 Italy Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 20 Spain Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 21 Spain Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 22 Sweden Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 23 Sweden Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 24 Norway Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 25 Norway Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 26 Denmark Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 27 Denmark Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 China Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 32 China Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 33 Japan Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 34 Japan Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 35 India Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 36 India Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 37 Australia Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 38 Australia Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 39 Thailand Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 40 Thailand Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 41 South Korea Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 42 South Korea Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 43 Latin America Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 44 Latin America Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 45 Latin America Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 47 Brazil Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 48 Mexico Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 49 Mexico Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 50 Argentina Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 51 Argentina Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa Gaucher disease drugs market, by region, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 57 South Africa Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 58 South Africa Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 59 UAE Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 60 UAE Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Gaucher disease drugs market, by type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Gaucher disease drugs market, by therapy, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Gaucher disease drugs: Market outlook
  • Fig. 9 Gaucher disease drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Gaucher disease drugs market driver impact
  • Fig. 15 Gaucher disease drugs market restraint impact
  • Fig. 16 Gaucher disease drugs market strategic initiatives analysis
  • Fig. 17 Gaucher disease drugs market: Type movement analysis
  • Fig. 18 Gaucher disease drugs market: Type outlook and key takeaways
  • Fig. 19 Type 1 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Type 2 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Type 3 market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Gaucher disease drugs market: Therapy movement analysis
  • Fig. 24 Gaucher disease drugs market: Therapy outlook and key takeaways
  • Fig. 25 Enzyme replacement therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Substrate replacement therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Global gaucher disease drugs market: Regional movement analysis
  • Fig. 29 Global gaucher disease drugs market: Regional outlook and key takeaways
  • Fig. 30 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)